Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).
The VEGF protein is an essential component of the angiogenesis pathway, critical for blood vessel formation, facilitating tumor growth, invasion, and metastasis. Inhibiting the VEGF protein leads to decreased blood vessel formation, thereby restricting nutrient intake and limiting tumor growth and development.
The drug was first approved for colorectal cancer in 2004, and then went on to gain approvals for lung, brain, ovarian, cervical, and renal cell cancer indications.
Key Topics Covered:
- Avastin: Colorectal cancer (CRC)
- Avastin: Retinal disorders
- Avastin: Ovarian cancer
- Avastin: Glioblastoma (GBM)
- Avastin: Renal cell cancer (RCC)
- Avastin: Non-small cell lung cancer (NSCLC)
- Avastin: Breast cancer: triple-negative
- Avastin: Breast cancer: HR+/HER2-
List of Figures (25 in Total)
Figure 1: Avastin for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Avastin for colorectal cancer
Figure 3: Drug assessment summary of Avastin for colorectal cancer
Figure 4: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
List of Tables (27 in Total)
Table 1: Avastin drug profile
Table 2: Overview of major approvals for Avastin in colorectal cancer
Table 3: Avastin Phase III data in colorectal cancer
Table 4: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016-25
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wbdpgq/avastin_global?w=4